Genmab A/S ADR (GMAB) News
Filter GMAB News Items
GMAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GMAB News Highlights
- For GMAB, its 30 day story count is now at 6.
- Over the past 12 days, the trend for GMAB's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- CELL, DRUG and ABBV are the most mentioned tickers in articles about GMAB.
Latest GMAB News From Around the Web
Below are the latest news stories about GENMAB A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug EpcoritamabThe FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug. |
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult PatientsThe FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Epkinly is being co-developed and co-commercialized by Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) as part of the companies' oncology collaboration. Epkinly features a dual-targeted approach continuously binding to T-cells and CD20+ lymphoma B-cell |
UPDATE 3-U.S. FDA approves Genmab-AbbVie's blood cancer therapyThe U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. The therapy, epcoritamab, which will be sold under the brand name Epkinly, treats a type of advanced large B-cell lymphoma, a cancer that starts in white blood cells. It is the first-of-its-kind therapy to be approved by the FDA for the disease which annually affects 150,000 people globally. |
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)COPENHAGEN, Denmark, May 19, 2023--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy. EPKINLY wa |
Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA reviewInvesting.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: new data from X4 Pharma, upcoming review dates for Krystal Biotech, and a torrent of news set for release at an annual biotech conference. |
Genmab Announces Financial Results for the First Quarter of 2023May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In the first quarter of the year we continued to lay the groundwork for the potential approval of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Looking beyond this indication, together with our partner AbbVie Inc. (AbbVie), we are committed to a robust clinical development progr |
Genmab To File Appeal in Its Second Arbitration Under License Agreement with JanssenCompany Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under its license agreement with Janssen Biotech, Inc. for daratumumab. The review of the award will be conducted by a single appeal arbitrator under the rules of the CPR Institute for Dispute Resolution for Non-Administered Arbitration. The arbitration remains confidential, subject to t |
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with JanssenCompany Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab. The arbitral tribunal dismissed Genmab’s claims, on the basis that they should have been brought in the first arbitration. One of the three arbitrators dissented. Genmab has the right to seek review of the award, which it must do within a limited period of time. Genmab is c |
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023Company Announcement Net sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson we |
Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |